Plenary Panel: How is Real World Data used to provide additional evidence for conditional regulatory approvals and initial reimbursement decisions?

Plenary Panel: How is Real World Data used to provide additional evidence for conditional regulatory approvals and initial reimbursement decisions?

Wednesday, November 4, 2020 8:10 AM to 9:20 AM · 1 hr. 10 min. (Africa/Abidjan)
Plenary Keynote

Information

- European initiatives exploring the potential for RWD to generate real-world evidence (RWE) that can inform key healthcare decisions about treatment efficacy, value and optimization of patient care

- What new initiatives are emerging in 2020 and how could they aid assessment of rare disease treatments

- The potential for better collaboration and joint learnings

- Followed by an open discussion with audience, ensuring to engage patient group leaders


TakedaTakeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Log in